Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

William C Olson

Showing results (51-60 of 73) with videos related to

Pageof 8
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 4, 2007
A novel alphavirus vaccine encoding prostate-specific membrane antigen elicits potent cellular and humoral immune responsesRobert J Durso, Sofija Andjelic, Jason P Gardner, et al.
Journal of Virology|July 5, 2002
Oligomeric and conformational properties of a proteolytically mature, disulfide-stabilized human immunodeficiency virus type 1 gp140 envelope glycoproteinNorbert Schülke, Mika S Vesanen, Rogier W Sanders, et al.
Virology|March 23, 2010
Lack of complex N-glycans on HIV-1 envelope glycoproteins preserves protein conformation and entry functionDirk Eggink, Mark Melchers, Manfred Wuhrer, et al.
Molecular Cancer Therapeutics|August 10, 2019
Preclinical Development of the Anti-LAG-3 Antibody REGN3767: Characterization and Activity in Combination with the Anti-PD-1 Antibody Cemiplimab in Human <i>PD-1xLAG-3</i>-Knockin MiceElena Burova, Aynur Hermann, Jie Dai, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 19, 2019
A Biparatopic Antibody That Modulates MET Trafficking Exhibits Enhanced Efficacy Compared with Parental Antibodies in MET-Driven Tumor ModelsJohn O DaSilva, Katie Yang, Andres E Perez Bay, et al.
Vaccine|July 2, 2009
Structural and immunogenicity studies of a cleaved, stabilized envelope trimer derived from subtype A HIV-1Yun Kenneth Kang, Sofija Andjelic, James M Binley, et al.
Proceedings of the National Academy of Sciences of the United States of America|June 29, 2011
Trimeric HIV-1 glycoprotein gp140 immunogens and native HIV-1 envelope glycoproteins display the same closed and open quaternary molecular architecturesAudray Harris, Mario J Borgnia, Dan Shi, et al.
The Journal of Biological Chemistry|May 31, 2012
Partial enzymatic deglycosylation preserves the structure of cleaved recombinant HIV-1 envelope glycoprotein trimersRafael S Depetris, Jean-Philippe Julien, Reza Khayat, et al.
Antimicrobial Agents and Chemotherapy|January 27, 2004
Treatment of advanced human immunodeficiency virus type 1 disease with the viral entry inhibitor PRO 542Jeffrey M Jacobson, Robert J Israel, Israel Lowy, et al.
The Prostate|January 22, 2019
Phase 1 study of PSMA ADC, an antibody-drug conjugate targeting prostate-specific membrane antigen, in chemotherapy-refractory prostate cancerDaniel P Petrylak, Philip Kantoff, Nicholas J Vogelzang, et al.
Pageof 8

Showing results (51-60 of 73) with videos related to

Sort By:
Pageof 8
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 4, 2007
A novel alphavirus vaccine encoding prostate-specific membrane antigen elicits potent cellular and humoral immune responsesRobert J Durso, Sofija Andjelic, Jason P Gardner, et al.
Journal of Virology|July 5, 2002
Oligomeric and conformational properties of a proteolytically mature, disulfide-stabilized human immunodeficiency virus type 1 gp140 envelope glycoproteinNorbert Schülke, Mika S Vesanen, Rogier W Sanders, et al.
Virology|March 23, 2010
Lack of complex N-glycans on HIV-1 envelope glycoproteins preserves protein conformation and entry functionDirk Eggink, Mark Melchers, Manfred Wuhrer, et al.
Molecular Cancer Therapeutics|August 10, 2019
Preclinical Development of the Anti-LAG-3 Antibody REGN3767: Characterization and Activity in Combination with the Anti-PD-1 Antibody Cemiplimab in Human <i>PD-1xLAG-3</i>-Knockin MiceElena Burova, Aynur Hermann, Jie Dai, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 19, 2019
A Biparatopic Antibody That Modulates MET Trafficking Exhibits Enhanced Efficacy Compared with Parental Antibodies in MET-Driven Tumor ModelsJohn O DaSilva, Katie Yang, Andres E Perez Bay, et al.
Vaccine|July 2, 2009
Structural and immunogenicity studies of a cleaved, stabilized envelope trimer derived from subtype A HIV-1Yun Kenneth Kang, Sofija Andjelic, James M Binley, et al.
Proceedings of the National Academy of Sciences of the United States of America|June 29, 2011
Trimeric HIV-1 glycoprotein gp140 immunogens and native HIV-1 envelope glycoproteins display the same closed and open quaternary molecular architecturesAudray Harris, Mario J Borgnia, Dan Shi, et al.
The Journal of Biological Chemistry|May 31, 2012
Partial enzymatic deglycosylation preserves the structure of cleaved recombinant HIV-1 envelope glycoprotein trimersRafael S Depetris, Jean-Philippe Julien, Reza Khayat, et al.
Antimicrobial Agents and Chemotherapy|January 27, 2004
Treatment of advanced human immunodeficiency virus type 1 disease with the viral entry inhibitor PRO 542Jeffrey M Jacobson, Robert J Israel, Israel Lowy, et al.
The Prostate|January 22, 2019
Phase 1 study of PSMA ADC, an antibody-drug conjugate targeting prostate-specific membrane antigen, in chemotherapy-refractory prostate cancerDaniel P Petrylak, Philip Kantoff, Nicholas J Vogelzang, et al.
Pageof 8